Document:

Exhibit 10.10

 

AMYLIN
PHARMACEUTICALS, INC.

2003 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN

STOCK OPTION AGREEMENT

(NONSTATUTORY STOCK OPTION)

 

Pursuant to your Stock Option
Grant Notice (“Grant Notice”) and this Stock Option Agreement, Amylin
Pharmaceuticals, Inc. (the “Company”) has granted you an option pursuant to the
Company’s 2003 Non-Employee Directors’ Stock Option Plan (the “Plan”) to
purchase the number of shares of the Company’s Common Stock indicated in your
Grant Notice at the exercise price indicated in your Grant Notice.  Options granted under the Plan are issued
under the Company’s 2009 Equity Incentive Plan or any successor equity
incentive plan thereto (the “Incentive Plan”), and any shares of the Company’s
Common Stock issued upon exercise of your option will be issued out of shares
reserved for issuance under the Incentive Plan. 
Defined terms not explicitly defined in this Stock Option Agreement but
defined in the Incentive Plan shall have the same definitions as in the
Incentive Plan except to the extent otherwise defined in the Plan.

 

The details of your option are
as follows:

 

1.             VESTING.  Subject to the limitations contained herein, your
option will vest as set forth in the Plan, provided that vesting will cease
upon the termination of your Continuous Service.

 

2.             NUMBER OF SHARES AND EXERCISE
PRICE.  The number of shares of Common Stock subject to your
option and your exercise price per share referenced in your Grant Notice may be
adjusted from time to time for capitalization adjustments, as provided in the
Plan.

 

3.             METHOD OF PAYMENT.  Payment of the exercise price is due in full upon
exercise of all or any part of your option. 
You may elect to make payment of the exercise price in cash or by check
or in any other manner permitted by your Grant Notice, which may include one or
more of the following:

 

(a)           In the Company’s sole discretion at the time your
option is exercised and provided that at the time of exercise the Common Stock
is publicly traded and quoted regularly in The Wall Street Journal, pursuant to
a program developed under Regulation T as promulgated by the Federal Reserve
Board that, prior to the issuance of Common Stock, results in either the
receipt of cash (or check) by the Company or the receipt of irrevocable instructions
to pay the aggregate exercise price to the Company from the sales proceeds.

 

(b)           Provided that at the time of exercise the Common Stock
is publicly traded and quoted regularly in The Wall Street Journal, by delivery
of already-owned shares of Common Stock either that you have held for the
period required to avoid a charge to the Company’s reported earnings (generally
six months) or that you did not acquire, directly or indirectly from the
Company, that are owned free and clear of any liens, claims, encumbrances or
security interests, and that are valued at Fair Market Value on the date of
exercise.  “Delivery” 

 

1

 

for these purposes, in
the sole discretion of the Company at the time you exercise your option, shall
include delivery to the Company of your attestation of ownership of such shares
of Common Stock in a form approved by the Company.  Notwithstanding the foregoing, you may not
exercise your option by tender to the Company of Common Stock to the extent
such tender would violate the provisions of any law, regulation or agreement
restricting the redemption of the Company’s stock.

 

(c)           Pursuant to the following deferred payment
alternative:

 

(i)            Not less than one hundred percent (100%) of the
aggregate exercise price, plus accrued interest, shall be due (i) on the
date designated by the Company in its sole and absolute discretion but not to
exceed four (4) years from date of exercise, or (ii) at the Company’s
election, upon termination of your Continuous Service.

 

(ii)           Interest shall be compounded at least annually and
shall be charged at the market rate of interest necessary to avoid a charge to
earnings for financial accounting purposes.

 

(iii)         At any time that the Company is incorporated in
Delaware, payment of the Common Stock’s “par value,” as defined in the Delaware
General Corporation Law, shall be made in cash and not by deferred payment.

 

(iv)          In order to elect the deferred payment alternative,
you must, as a part of your written notice of exercise, give notice of the
election of this payment alternative and, in order to secure the payment of the
deferred exercise price to the Company hereunder, if the Company so requests,
you must tender to the Company a promissory note and a security agreement covering
the purchased shares of Common Stock, both in form and substance satisfactory
to the Company, or such other or additional documentation as the Company may
request.

 

4.             WHOLE SHARES.  You may exercise your option only for whole shares of
Common Stock.

 

5.             SECURITIES LAW COMPLIANCE.  Notwithstanding anything to the contrary contained
herein, you may not exercise your option unless the shares of Common Stock
issuable upon such exercise are then registered under the Securities Act or, if
such shares of Common Stock are not then so registered, the Company has
determined that such exercise and issuance would be exempt from the
registration requirements of the Securities Act.  The exercise of your option must also comply
with other applicable laws and regulations governing your option, and you may
not exercise your option if the Company determines that such exercise would not
be in material compliance with such laws and regulations.

 

6.             TERM.  You may not exercise your option before the
commencement of its term or after its term expires.  The term of your option commences on the Date
of Grant and expires upon the earliest of the following:

 

(a)           subject to Section 6(f), three (3) months
after the termination of your Continuous Service for any reason other than your
Disability or death, provided that if during 

 

2

 

any part of such three (3) month
period your option is not exercisable solely because of the condition set forth
in the preceding paragraph relating to “Securities Law Compliance,” your option
shall not expire until the earlier of the Expiration Date or until it shall
have been exercisable for an aggregate period of three (3) months after
the termination of your Continuous Service;

 

(b)           subject to Section 6(f), twelve (12) months after
the termination of your Continuous Service due to your Disability;

 

(c)           subject to Section 6(f), twelve (12) months after
your death if you die either during your Continuous Service or within three (3) months
after your Continuous Service terminates;

 

(d)           the Expiration Date indicated in your Grant Notice;

 

(e)           the day before the seventh (7th) anniversary of the
Date of Grant; or

 

(f)            in the event that your Continuous Service terminates
without Cause (as defined below) or because of your Disability or death, in any
such case at a time when you are 55 years old or older and have Continuous
Service of 5 years or more, then, to the extent you were entitled to exercise
your option at the date of such termination, your option will expire upon the
earliest of the fifth anniversary of such date, the Expiration Date indicated
in your Grant Notice, or the day before the tenth (10th) anniversary of the Date of Grant.

 

For purposes of this Section 6(f) only,
“Cause” means that, in the reasonable determination of the Company, you have (i) been
convicted of or pleaded guilty or nolo contendere
to a felony or any crime involving moral turpitude or dishonesty; (ii) participated
in a fraud or act of dishonesty against the Company; (iii) willfully and
materially breached a Company policy; (iv) intentionally damaged the
Company’s property; (v) willfully and materially breached your Proprietary
Information and Inventions Agreement with the Company; (vi) engaged in
conduct that, in the reasonable determination of the Company, demonstrates
gross unfitness to serve; or (vii) repeatedly failed to satisfactorily
perform job duties to which you previously agreed in writing.  The conduct described under clauses (iii), (vi) and
(vii) above will only constitute Cause if such conduct is not cured within
90 days after your receipt of written notice from the Company or the Board
specifying the particulars of the conduct that may constitute Cause.

 

7.             EXERCISE.

 

(a)           You may exercise the vested portion of your option
during its term by delivering a Notice of Exercise (in a form designated by the
Company) together with the exercise price to the Secretary of the Company, or
to such other person as the Company may designate, during regular business
hours, together with such additional documents as the Company may then require.

 

(b)           By exercising your option you agree that, as a
condition to any exercise of your option, the Company may require you to enter
into an arrangement providing for the payment by you to the Company of any tax
withholding obligation of the Company arising by reason of (1) the
exercise of your option, (2) the lapse of any substantial risk of
forfeiture to 

 

3

 

which the shares of
Common Stock are subject at the time of exercise, or (3) the disposition
of shares of Common Stock acquired upon such exercise.

 

8.             TRANSFERABILITY.  Your option is not transferable, except by will or by
the laws of descent and distribution, and is exercisable during your life only
by you.  Notwithstanding the foregoing,
by delivering written notice to the Company, in a form satisfactory to the
Company, you may designate a third party who, in the event of your death, shall
thereafter be entitled to exercise your option.

 

9.             OPTION NOT A SERVICE CONTRACT.  Your option is not a service contract, and nothing in
your option shall be deemed to create in any way whatsoever any obligation on
your part to continue in the service of the Company as a Director, or of the
Company to continue your service as a Director. 
Nothing in your option shall obligate the Company or an Affiliate, their
respective stockholders, Boards of Directors, Officers or Employees to continue
your relationship with the Company as a Director.

 

10.          WITHHOLDING OBLIGATIONS.

 

(a)           At the time you exercise your option, in whole or in
part, or at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and
otherwise agree to make adequate provision for (including by means of a “cashless
exercise” pursuant to a program developed under Regulation T as promulgated by
the Federal Reserve Board to the extent permitted by the Company), any sums
required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or an Affiliate, if any, which arise in connection
with your option.

 

(b)           Upon your request and subject to approval by the
Company, in its sole discretion, and compliance with any applicable conditions
or restrictions of law, the Company may withhold from fully vested shares of
Common Stock otherwise issuable to you upon the exercise of your option a
number of whole shares of Common Stock having a Fair Market Value, determined
by the Company as of the date of exercise, not in excess of the minimum amount
of tax required to be withheld by law. 
If the date of determination of any tax withholding obligation is
deferred to a date later than the date of exercise of your option, share
withholding pursuant to the preceding sentence shall not be permitted unless
you make a proper and timely election under Section 83(b) of the
Code, covering the aggregate number of shares of Common Stock acquired upon
such exercise with respect to which such determination is otherwise deferred,
to accelerate the determination of such tax withholding obligation to the date
of exercise of your option. 
Notwithstanding the filing of such election, shares of Common Stock
shall be withheld solely from fully vested shares of Common Stock determined as
of the date of exercise of your option that are otherwise issuable to you upon
such exercise.  Any adverse consequences
to you arising in connection with such share withholding procedure shall be
your sole responsibility.

 

(c)           You may not exercise your option unless the tax
withholding obligations of the Company and/or any Affiliate are satisfied.  Accordingly, you may not be able to exercise
your option when desired even though your option is vested, and the Company
shall have no 

 

4

 

obligation to issue a
certificate for such shares of Common Stock or release such shares of Common
Stock from any escrow.

 

11.          NOTICES.  Any notices provided for in your option or the Plan
shall be given in writing and shall be deemed effectively given upon receipt
or, in the case of notices delivered by mail by the Company to you, five (5) days
after deposit in the United States mail, postage prepaid, addressed to you at
the last address you provided to the Company.

 

12.          GOVERNING PLAN DOCUMENT.  Your option is subject to all the provisions of the
Incentive Plan except to the extent otherwise provided for in the Plan, the
respective provisions of which are hereby made a part of your option, and is
further subject to all interpretations, amendments, rules and regulations
which may from time to time be promulgated and adopted pursuant to the
Incentive Plan except to the extent otherwise provided for in the Plan or any
amendments, rules and regulations which may from time to time be promulgated
and adopted pursuant to the Plan.  In the
event of any conflict between the provisions of your option and those of the
Incentive Plan or the Plan, as applicable, the provisions of the Incentive Plan
or the Plan shall control, as the case may be.

 

5Exhibit 10.26

 

Summary
Description of Named Executive Officer

Oral At-Will Employment Agreement

 

With
the exception of Daniel M. Bradbury, our President and Chief Executive Officer,
with whom we have a written employment agreement, we maintain oral at-will
employment relationships with each of our other currently-serving named
executive officers: Mark G. Foletta, Orville G. Kolterman, M.D., Marcea Bland
Lloyd and Vincent Mihalik. Each of these executive officers receives our normal
and customary employment benefits, generally on the same terms as all of our
employees. The benefits include the right to (i) participate in our 401(k) Plan
and our Employee Stock Purchase Plan, (ii) receive 10% of eligible
compensation in the form of Amylin common stock under our Employee Stock
Ownership Plan and (iii) receive stock option grants under our Equity
Incentive Plan and cash bonuses under our cash bonus plan. Each of these
executive officers is also eligible, along with all of our employees holding
the title of vice-president and above, to participate in our Deferred
Compensation Plan and our Officer Change in Control Severance Benefit Plan. The
Change in Control Plan provides each participant with certain benefits in the
event such employee ceases employment with Amylin without cause or under
certain specified circumstances and within 90 days prior to, or within 13
months following specified change of control transactions.  In such event,
(i) the president and chief executive officer would receive salary
continuation for 36 months and three times his annual target bonus; (ii) executive
officers would receive salary continuation for 24 months and two times their
annual target bonus, and (iii) non-executive officers would receive 18
months salary continuation and an amount equal to their annual target
bonus.  Under the Change in Control Plan,
officers would also receive 18 months of certain COBRA payment
reimbursement.  We also have customary indemnification agreements with our
officers, including these executive officers. In addition, the Compensation and
Human Resources Committee of our Board of Directors reviews the salaries of our
executive officers from time to time.  Mr. Bradbury’s annual salary
is currently set at $675,000. Annual salaries for each of our other named executives
are currently set as follows:  Dr. Kolterman
- $440,000, Mr. Foletta - $419,750, Ms. Lloyd - $400,125 and Mr. Mihalik
- $375,000.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]